Europe High Throughput Screening Market
High-throughput screening (HTS) is a drug discovery process that allows automated testing of large numbers of chemical and/or biological compounds for a specific biological target. High-throughput screening methods are extensively used in the pharmaceutical industry, leveraging robotics and automation to quickly test the biological or biochemical activity of many molecules, usually drugs. They accelerate target analysis, as large-scale compound libraries can quickly be screened in a cost-effective way. HTS is a useful tool for assessing for instance pharmacological targets, pharmacologically profiling agonists and antagonists for receptors (such as GPCRs) and enzymes.
Strategic insights for the Europe High Throughput Screening provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 4,968.81 Million |
| Market Size by 2028 | US$ 8,578.43 Million |
| Global CAGR (2021 - 2028) | 8.1% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product and Service
|
| Regions and Countries Covered | Europe
|
| Market leaders and key company profiles |
The geographic scope of the Europe High Throughput Screening refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The Europe high throughput screening market is expected to reach US$ 8,578.43 million in 2028 from US$ 4,968.81 million in 2021; it is estimated to register a CAGR of 8.1% from 2021 to 2028. Driving factors such as an increase in investment in research and development by the pharmaceutical and biotechnology industry and the introduction of technologically advanced products in the high throughput screening market are driving the growth of the market. However, the lack of proper automation methods is obstructing the growth of the market.
The market is witnessing the use of artificial intelligence (AI) in high-throughput screening (HTS). Using AI in HTS is an important objective of the pharmaceutical and biotech industry. Using AI-based data processing/control software, liquid handling systems, and sensitive detectors, and high-throughput screening allows a researcher to quickly conduct millions of chemicals, genetic, or pharmacological tests. Through this process, one can rapidly identify active compounds, antibodies, or genes that modulate a biomolecular pathway. Most of the top biopharmaceutical companies have started internal programs and are collaborating to develop AI platforms for increasing the research power of immuno-oncology drugs, metabolic-disease therapies, cancer treatments, and many other therapeutic targets. In July 2020, Cerevel Therapeutics—a company dedicated to research and development in neuroscience diseases therapeutics—and Cyclica—an AI-based drug discovery company—entered into a collaboration to accelerate the discovery of novel medicines in neuroscience. Cyclica’s world-class AI platform for high-throughput screening in compound identification and optimization can efficiently identify new therapeutic molecules for Cerevel Therapeutics. Such strategic developments show that AI-based high-throughput screening technologies will revolutionize drug discovery. Furthermore, there is an increase in demand for high-throughput screening owing to the need for screening new chemical entities with more efficiency, as well as ensure productive optimization of drug molecules. Technological advancements in high-throughput screening techniques and the launch of innovative systems by various market players are driving the market growth.
The European economy is severely affected due to the exponential growth of COVID-19 cases in the region. Due to the second wave of COVID-19 cases, the governments of many countries are working toward scaling up testing capacity, which is driving the growth of the market. Many pharmaceutical companies in the region are actively engaged in the development of COVID-19 vaccine and drugs. Moreover, as part of the UK government’s announcement of a new plan to boost testing for COVID-19, GSK, AstraZeneca, and the University of Cambridge have collaborated to take action to support this national effort for boosting the testing segment. A new testing laboratory will be set up by GSK, AstraZeneca, and Anne McLaren laboratory- University of Cambridge. This facility will be used for high-throughput screening for COVID-19 testing and to explore the use of alternative chemical reagents for test kits in order to help overcome supply shortages. These factors will help boost the market growth.
The Europe high throughput screening market, based on product and service, is subsegmented into consumables, instruments, accessories, software, and services. The consumables segment is further subsegmented into reagents, assay kits, and laboratory equipment. Furthermore, the instruments are sub-divided into liquid handling systems and detection systems. In 2021, the consumables segment is expected to hold the largest share of the market and is expected to register the highest CAGR during 2021–2028.
The Europe high throughput screening market, based on the technology, is segmented into cell-based assays, lab-on-a-chip, ultra-high-throughput screening, bioinformatics, and label-free technology. In 2021, the cell-based assays segment is expected to hold the largest share of the market; however, the lab-on-a-chip segment is expected to register the highest CAGR during the forecast period.
The Europe high throughput screening market, based on application, is segmented into drug discovery, biochemical screening, life sciences research, and other applications. In 2021, the drug discovery segment is expected to hold the largest share of the market and is expected to register the highest CAGR during the forecast period.
The Europe high throughput screening market, based on end user, is subsegmented into pharmaceutical and biotechnology companies, academic and government institutes, contract research organizations (CRO), and others. In 2021, the pharmaceutical and biotechnology companies segment is expected to hold the largest share of the market. However, the contract research organizations (CRO) segment is expected to register the highest CAGR during the forecast period.
A few of the primary and secondary sources associated with this report on the Europe high throughput screening market are the European Society of Cardiology (ESC), Federal Ministry for Economic Affairs and Energy (BMWi) and National Health Service (NHS).
The Europe High Throughput Screening Market is valued at US$ 4,968.81 Million in 2021, it is projected to reach US$ 8,578.43 Million by 2028.
As per our report Europe High Throughput Screening Market, the market size is valued at US$ 4,968.81 Million in 2021, projecting it to reach US$ 8,578.43 Million by 2028. This translates to a CAGR of approximately 8.1% during the forecast period.
The Europe High Throughput Screening Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe High Throughput Screening Market report:
The Europe High Throughput Screening Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe High Throughput Screening Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe High Throughput Screening Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe High Throughput Screening Market
